Evidence map›Paper›PMID 23013206›Full record

ArticleMolecular pharmaceutics2012

Chemically self-assembled antibody nanostructures as potential drug carriers.

Adrian Fegan, Sidath C Kumarapperuma, Carston R Wagner

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Liposomes in Cancer Therapy: How Did We Start and Where Are We Now.International journal of molecular sciences · 2023
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Simultaneous dual protein labeling using a triorthogonal reagent.Journal of the American Chemical Society · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Adrian FeganDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Sidath C Kumarapperuma
Carston R Wagner
University of Minnesota · US

Funding

Chemically Controlled Assembly of Therapuetic Protein NanostrcturesR01CA120116 · NCI · UNIVERSITY OF MINNESOTA · PI WAGNER, CARSTON R. · 2007 to 2010
$1.2M
Self-Assemblying Immunotherapeutic NanoringsR01CA125360 · NCI · UNIVERSITY OF MINNESOTA · PI WAGNER, CARSTON R. · 2008 to 2011
$1.2M
NCI NIH HHS CA120116NCI NIH HHS CA125360NCI NIH HHS R01 CA120116NCI NIH HHS R01 CA125360
6 · The paper itself

Abstract

Chemically self-assembled antibody nanorings (CSANs) displaying multiple copies of single-chain variable fragments can be prepared from dihydrofolate reductase (DHFR) fusion proteins and bis-methotrexate (bisMTX). We have designed and synthesized a bisMTX chemical dimerizer (bisMTX-NH(2)) that contains a third linker arm that can be conjugated to fluorophores, radiolabels, and drugs. Monovalent, divalent, and higher-order AntiCD3 CSANs were assembled with a fluorescein isothiocyanate (FITC)-labeled bis-methotrexate ligand (bisMTX-FITC) and found to undergo rapid internalization and trafficking by HPB-MLT, a CD3+ T-leukemia cell line, to the early and late endosome and lysosome. Because the fluorescence of bisMTX-FITC when incorporated into CSANs was found to be significantly greater than that of the free ligand, the stability of the endocytosed AntiCD3 CSANs could be monitored. The internalized CSANs were found to be stable for several hours, while treatment with the nontoxic DHFR inhibitor trimethoprim resulted in a rapid loss (>80%) of cellular fluorescence within minutes, consistent with efficient intracellular disassembly of the nanorings. Over longer time periods (24 h), cellular fluorescence decreased by 75-90%, regardless of whether cells had been treated with DMSO or trimethoprim. Although bisMTX is a potent inhibitor of DHFR, it was found to be nontoxic (GI(50) > 20 μM) to HPB-MLT cells. In contrast, AntiCD3 CSANs prepared with bisMTX were found to be at least 13-fold more cytotoxic (GI(50) = 0.5-1.5 μM) than bisMTX at 72 h. Consistent with our findings from CSAN stability studies, no increase in cytotoxicity was observed upon treatment with trimethoprim. Taken together, our results suggest that cell receptor targeting CSANs prepared with trifunctional bisMTX could be used as potential tissue selective drug carriers.

Indexed as

Drug CarriersNanostructuresAntibodies, MonoclonalCD3 ComplexCell ProliferationChromatography, GelFlow CytometryHumansLeukemia, T-CellMethotrexateMicroscopy, ConfocalMicroscopy, FluorescenceRecombinant Fusion ProteinsSingle-Chain AntibodiesTetrahydrofolate DehydrogenaseAntibodies, MonoclonalCD3 ComplexDrug CarriersMethotrexateRecombinant Fusion ProteinsSingle-Chain AntibodiesTetrahydrofolate Dehydrogenase

Identifiers

PMID23013206
PMCPMC3549309
OpenAlexW2168057921

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.